Join List

In this article, Servier CMC leader Dr. Thuy Tran gives us a quick explanation of what an IND is, what a clinical hold is, and why clinical holds happen for drug discovery scientists.

Most drug hunters will be involved in an IND filing at some point, whether it is providing supporting data, or organizing an entire submission on behalf of your company.

Here’s a look at what our CMC and regulatory affairs partners quarterback for us every time we want to run a new trial or something goes wrong, so you have an idea of how to thank them at the next company happy hour.
Read the Full Article
What were the billion-dollar small molecule biotechs in 2021?
One example from 2021 is the acquisition of Constellation Pharmaceuticals by MorphoSys AG for up to $1.7B. At the time of the acquisition, Constellation focused on epigenetic drugs including pelabresib (CPI-0610), a BET bromodomain inhibitor, and …
Continue Reading
What were the billion-dollar large molecule biotechs in 2021?
One example from 2021 is the acquisition of Acceleron by Merck for up to $11.5B. Interestingly, the lead, sotatercept, is intended for cardiology (pulmonary aterial hypertension), a space that has been difficult in recent years and has not had nearly as much success from large molecules or biologics are other areas such as oncology or immunology.

The lead molecule, Ph. III asset sotatercept, is interesting because...
Keep Reading

Tired of trying to figure out how much compound you need to make for that toxicology study?

Want an estimate of human dose based on an animal study?

Check out these new calculators...

Animal Study Planner
Human Dose Estimator
Apr. 26th event
Drug Discovery Highlights from Q1 2022
Drug Hunter "Flashtalk" Virtual Event
Join us in two days for our premier Drug Hunter webinar in which we cover interesting drug discovery highlights from our articles in the first quarter of 2022, including drug approvals, Molecules of the Month, industry conferences, and other industry developments.

​The format is a Flash Talk, in which we'll quickly cover the key details so you can get caught up over a coffee break, followed by a discussion section in which we'll review questions and letters from audience members.

share Drug Hunter
Know drug hunters that would find this newsletter helpful? Give them your unique referral link (below) to let them sign up too. We'll be raffling off fun things to top referrers, stay tuned~
PS: You have referred <<RH_TOTREF>> people so far
more recent content
Here's a recap of other stories recently published on Drug Hunter:
  1. Molecules of the Month - Mar. 2022
  2. Practical PK Calculators
  3. Drug Discovery M&A Upfront Payments in 2021
  4. Top 10 Drug Discovery M&A Transaction in 2021
  5. Solid Form Strategies for Increasing Oral Bioavailability
  6. Letters from Drug Hunters #1 – Apr. 2022
  7. New Drug Candidates at AACR New Orleans 2022
  8. Sisunatovir, Oral Ph. II RSV Candidate, to Be Acquired by Pfizer
  9. In Context: First-Time Disclosures of ACS Spring 2022
  10. March 2022 Novel Drug Approvals
  11. 2022 FDA Novel Drug Approvals to Date
  12. Molecules of the Month - February 2022
Want to dive deeper into the science behind industrial drug discovery? Get access to Premium for your team at a group rate by contacting us.
featured careers
Vice President,  Medicinal Chemistry
Pin Therapeutics, South San Francisco, CA

Executive Director,  Medicinal Chemistry
Vertex, San Diego, CA

Senior Vice President, Head of Drug Discovery
Genentech/Roche (gRED), South San Francisco, CA
See All Careers
Share an Opportunity
discover together

Join List
Copyright © 2022 Drug Hunter Inc., All rights reserved.
You can change how often you receive messages by updating your preferences or remove yourself from this list. Having trouble? Contact us directly.